<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01041495</url>
  </required_header>
  <id_info>
    <org_study_id>amrixfm001</org_study_id>
    <nct_id>NCT01041495</nct_id>
  </id_info>
  <brief_title>Cyclobenzaprine Extended Release (ER) for Fibromyalgia</brief_title>
  <official_title>An Eight Week, Double-Blind Efficacy Study of Cyclobenzaprine ER (Amrix TM) Augmentation to Alleviate Fibromyalgia Fatigue and Muscle Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York - Upstate Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>State University of New York - Upstate Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amrix (Cyclobenzaprine hydrochloride Extended release capsules) is approved by the FDA as a&#xD;
      muscle relaxant, indicated for the treatment of muscle spasm associated with acute, painful&#xD;
      musculoskeletal conditions. Cyclobenzaprine ER (Amrix TM) has a distinct pharmacokinetic&#xD;
      profile providing early systemic exposure and consistent plasma concentration over several&#xD;
      hours. Overall, a single dose of Amrix 30 mg is similar to that of cyclobenzaprine immediate&#xD;
      release 10 mg three times daily. This ER formula should improve compliance, with similar&#xD;
      efficacy and possibly less side effects as is often the case with slower release&#xD;
      formulations.&#xD;
&#xD;
      There are clinical studies showing that cyclobenzaprine can alleviate pain secondary to&#xD;
      Fibromyalgia induced muscle tone. This multi-layered evidence base suggests that&#xD;
      cyclobenzaprine may be able to alleviate pain in fibromyalgia. Theoretically in fibromyalgia,&#xD;
      pain is interpreted centrally and possibly occurs due to said muscle spasm . Cyclobenzaprine&#xD;
      may relieve this pain, thus allowing patients to function better during the day and sleep&#xD;
      better at night. Cyclobenzaprine has tricyclic antidepressant structure which may also allow&#xD;
      pain signal dampening in the spinal cord as well, similar to amitriptyline which is used&#xD;
      off-label for neuropathic pain as well.&#xD;
&#xD;
      Fibromyalgia (FM) is an illness that may involve medical, rheumatologic, autoimmune, sleep,&#xD;
      endocrine and psychiatric pathology. It is a syndrome of recurrent pain at trigger points.&#xD;
      Greater than 90% of these patients will report fatigue as a key symptom as well. There are&#xD;
      several investigation lines into the treatment of FM induced pain. Exercise, behavioral&#xD;
      therapy, amitryptiline, duloxetine, tramadol, sodium oxybate, pregabalin all have randomized&#xD;
      trials and almost all focus on pain. There are very few studies evaluating cyclobenzaprine&#xD;
      and none studying to Cyclobenzaprine ER formulation. None evaluate pain reduction, sleep and&#xD;
      fatigue improvement.&#xD;
&#xD;
      Cyclobenzaprine is a drug with minimal adverse effects (dry mouth, dizziness, fatigue,&#xD;
      constipation, somnolence, nausea, and dyspepsia). It may have a safer tolerability profile&#xD;
      than some of the FM medications noted above. As cyclobenzaprine is often studied and often&#xD;
      added as an augmentation agent to patients' regimens who suffer from acute painful&#xD;
      musculoskeletal conditions, the authors feel that cyclobenzaprine would also be effective in&#xD;
      this population. The authors wish to conduct a study to determine if cyclobenzaprine ER is&#xD;
      safe and tolerable in the treatment of FM induced pain, and secondary fatigue and insomnia.&#xD;
      This initial study may allow for continued regulatory studies with this product in FM&#xD;
      subjects. The authors propose a double-blind placebo controlled study to determine if&#xD;
      cyclobenzaprine ER is safe and effective in reversing FM induced pain, and secondary fatigue&#xD;
      and insomnia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    ran out of funding short of enrollment expected&#xD;
  </why_stopped>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analogue Pain Scale at 8 Weeks Post Treatment</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in baseline subjective pain based on a 10 point scale (1= no pain, 10 = severe pain) from baseline (T=Zero, prior to drug/placebo treatment) to week 8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief Fatigue Inventory at 8 Weeks Post Treatment</measure>
    <time_frame>baseline to 8 weeks</time_frame>
    <description>Change in baseline subjective fatigue based on this scale (1= no fatigue, 10 = severe fatigue) from baseline (T=Zero, prior to drug/placebo treatment) to week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibromyalgia Impact Questionnaire Scores at 8 Weeks Post Treatment</measure>
    <time_frame>from baseline to 8 weeks</time_frame>
    <description>Change in baseline subjective fibromyalgia symptoms based on a 100 point scale (0 = no fibromyalgia or minimum score, 100 = severe fibromyalgia and maximal score) from baseline (T=Zero, prior to drug/placebo treatment) to week 8</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Fibromyalgia</condition>
  <condition>Pain</condition>
  <condition>Sleep</condition>
  <condition>Fatigue</condition>
  <arm_group>
    <arm_group_label>cyclobenzaprine ER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclobenzaprine ER (AMRIX)</intervention_name>
    <description>active drug</description>
    <arm_group_label>cyclobenzaprine ER</arm_group_label>
    <other_name>AMRIX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching placebo for AMRIX</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        If possible, 60 subjects will be included in this study.&#xD;
&#xD;
          -  All males/females of any race are eligible if aged between 18 and 65 and&#xD;
&#xD;
          -  Subjects must speak English and have capacity to receive and utilize informed consent&#xD;
&#xD;
          -  Agree to use barrier method contraception or are infertile x 2 years due to medical&#xD;
             condition or surgery&#xD;
&#xD;
          -  Have been formally diagnosed by a Board Certified Rheumatologist using the ACR 1990&#xD;
             research criteria for fibromyalgia&#xD;
&#xD;
          -  Report that pain is a key distressing symptom of their FM&#xD;
&#xD;
          -  Have a score of &gt; 4 on the Visual Analogue Pain Scale (VAPS)&#xD;
&#xD;
        Exclusion Criteria: Subjects cannot&#xD;
&#xD;
          -  Be pregnant or be attempting to conceive at present (urine bHCG must be negative)&#xD;
&#xD;
          -  Have an active substance abuse problem with last use within the past 90 days (outside&#xD;
             of nicotine)&#xD;
&#xD;
          -  Use cardiac QTc prolonging medications i.e., tricyclic antidepressants&#xD;
&#xD;
          -  Use p4502D6 major inhibiting medications as cyclobenzaprine levels may increase&#xD;
&#xD;
          -  Have a known medical condition outside of FM that causes pain, i.e., diabetic&#xD;
             neuropathy&#xD;
&#xD;
          -  Have a known medical condition or other medication use that relatively contraindicates&#xD;
             cyclobenzaprine use (i.e., hypersensitivity concomitant use of monoamine oxidase (MAO)&#xD;
             inhibitors, seizures, known cardiac abnormalities, recent MI. hepatitis, stroke, or&#xD;
             psychosis&#xD;
&#xD;
          -  Has a prior history of cyclobenzaprine use and failure (failure due to side effects&#xD;
             may be allowed at P.I. discretion)&#xD;
&#xD;
          -  Be receiving daytime/nighttime sedating medication with clear chronological impact on&#xD;
             fatigue UNLESS fatigue predates sedating medication or said medication has been&#xD;
             steadily dosed &gt; 4 weeks&#xD;
&#xD;
          -  Other medications known to alleviate pain (i.e., Gabapentin, Pregabalin,&#xD;
             Amitryptiline, Duloxetine,Venlafaxine, Carbamazepine, Tramadol, etc) unless they have&#xD;
             been at steady dose more than 6 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>thomas l schwartz, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>SUNY Upstate</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 29, 2009</study_first_submitted>
  <study_first_submitted_qc>December 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2009</study_first_posted>
  <results_first_submitted>December 9, 2014</results_first_submitted>
  <results_first_submitted_qc>October 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 6, 2021</results_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York - Upstate Medical University</investigator_affiliation>
    <investigator_full_name>Thomas L. Schwartz, M.D.</investigator_full_name>
    <investigator_title>Assoc Professor</investigator_title>
  </responsible_party>
  <keyword>fibromyalgia</keyword>
  <keyword>Pain</keyword>
  <keyword>Sleep</keyword>
  <keyword>Fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclobenzaprine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>radio and billboard ads were used to recruit subjects who were then screened a a psychiatric based practice</recruitment_details>
      <pre_assignment_details>subjects had to meet eligibility criteria</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cyclobenzaprine ER</title>
          <description>active muscle relaxant medication</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>matching placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cyclobenzaprine ER</title>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Analogue Pain Scale at 8 Weeks Post Treatment</title>
        <description>Change in baseline subjective pain based on a 10 point scale (1= no pain, 10 = severe pain) from baseline (T=Zero, prior to drug/placebo treatment) to week 8</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cyclobenzaprine ER</title>
            <description>cyclobenzaprine ER (AMRIX): active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: matching placebo for AMRIX</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Pain Scale at 8 Weeks Post Treatment</title>
          <description>Change in baseline subjective pain based on a 10 point scale (1= no pain, 10 = severe pain) from baseline (T=Zero, prior to drug/placebo treatment) to week 8</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O2" value="5.7" lower_limit="5" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>.869</p_value>
            <p_value_desc>P values below 0.05 were considered statistically significant</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>.869</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Fatigue Inventory at 8 Weeks Post Treatment</title>
        <description>Change in baseline subjective fatigue based on this scale (1= no fatigue, 10 = severe fatigue) from baseline (T=Zero, prior to drug/placebo treatment) to week 8</description>
        <time_frame>baseline to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cyclobenzaprine ER</title>
            <description>cyclobenzaprine ER (AMRIX): active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: matching placebo for AMRIX</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Fatigue Inventory at 8 Weeks Post Treatment</title>
          <description>Change in baseline subjective fatigue based on this scale (1= no fatigue, 10 = severe fatigue) from baseline (T=Zero, prior to drug/placebo treatment) to week 8</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O2" value="4.8" lower_limit="4" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>.486</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.486</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fibromyalgia Impact Questionnaire Scores at 8 Weeks Post Treatment</title>
        <description>Change in baseline subjective fibromyalgia symptoms based on a 100 point scale (0 = no fibromyalgia or minimum score, 100 = severe fibromyalgia and maximal score) from baseline (T=Zero, prior to drug/placebo treatment) to week 8</description>
        <time_frame>from baseline to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cyclobenzaprine ER</title>
            <description>cyclobenzaprine ER (AMRIX): active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: matching placebo for AMRIX</description>
          </group>
        </group_list>
        <measure>
          <title>Fibromyalgia Impact Questionnaire Scores at 8 Weeks Post Treatment</title>
          <description>Change in baseline subjective fibromyalgia symptoms based on a 100 point scale (0 = no fibromyalgia or minimum score, 100 = severe fibromyalgia and maximal score) from baseline (T=Zero, prior to drug/placebo treatment) to week 8</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="36" upper_limit="59"/>
                    <measurement group_id="O2" value="51" lower_limit="40" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>.869</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>17</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.275</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>17</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During acute study (8 Weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cyclobenzaprine ER</title>
          <description>active drug</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>inactive placebo matching</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>glucosemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Recruitment was halted as advertisements failed to bring in enough subjects.There were 37 enrollees: some screen failed, never started protocol,lost to follow up, some data not analyzable affording 28 subjects to be included</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>thomas schwartz</name_or_title>
      <organization>SUNY Upstate MEdical Univ</organization>
      <phone>3154643166</phone>
      <email>schwartt@upstate.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

